ClinicalTrials.gg
CompletedNCT02932774Updated Apr 20, 2017

Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)

A Phase 4 interventional study of Cetirizine and Loratadine in Allergic Rhinitis, Hay Fever and SAR, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-04-20.

Primary conditionRhinitis, Allergic, SeasonalRegistry: Rhinitis, AllergicReclassifiedWhy we changed it
Registry
Rhinitis, Allergic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Rhinitis, Allergic, Seasonal
Why
  1. The study's listed conditions name Rhinitis, Allergic, Seasonal, a narrower term within Rhinitis, Allergic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
683
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. Cetirizine · Rhinitis, Allergic, Seasonal.

Enrollment
Largest of 10
683 · median 117
Started
2001
the only one that year
Phase 4
6 of 10
none open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Johnson & Johnson Consumer and Personal Products Worldwide

Among the 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal, this one has the largest enrollment, is the only one that started in 2001, is one of 6 in phase 4, and was the 10th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

About cetirizine

Cetirizine: first FDA approval 1995 (ZYRTEC HIVES). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing cetirizine in Rhinitis, Allergic, Seasonal as a file.
02

Study summary

The objective of this clinical trial was to assess the efficacy and safety of cetirizine HCl syrup vs. loratadine syrup vs. placebo syrup in the treatment of SAR in children 6 to 11 years old.

Read the detailed description

This was a multi-center, randomized, double-blind, parallel-group, placebo-controlled, double dummy study of children with SAR conducted during the Spring tree and grass allergy season. Subjects qualified for randomization if the diary cards included (1) symptom scores of ≥2 for at least 2 of the following 4 rhinoconjunctivitis symptoms on 4 or more days: sneezing, runny nose, itchy eyes, and watery eyes; and (2) a total rhinoconjunctivitis (or Total Symptom Severity Complex [TSSC]) score of ≥5 on any 4 days. The TSSC score was expressed as the sum of the 4 individual symptoms scores recorded in the daily diary cards for the following symptoms: sneezing, runny nose, itchy eyes, and watery eyes.

Subjects were randomized to receive 1 of 3 treatments in a double-blind fashion using a 1:1:1 allocation ratio: cetirizine HCl syrup and placebo loratadine syrup; loratadine syrup and placebo cetirizine HCl syrup; or cetirizine placebo syrup and loratadine placebo syrup.

Number of Subjects (Planned and Analyzed): 1100 planned; 1536 screened; 683 randomized: 231 (33.8%) randomized to the cetirizine HCl treatment group, 221 (32.4%) to the loratadine treatment group, and 231 (33.8%) to the placebo treatment group.

Test Product and Reference Therapy: Subjects randomized to receive cetirizine HCl syrup also received placebo syrup; subjects randomized to receive loratadine syrup also received placebo syrup; and both placebo syrups were received by subjects randomized to receive placebo.

Duration of Double-Blind Treatment: 2 weeks.

Safety measures included the incidence and severity of treatment-emergent adverse events (AEs), vital signs, concomitant medications, and physical examination findings. Clinical laboratory evaluation was not required for this study.

Statistical Methods: All statistical tests related to treatment effect were 2-sided, and statistical significance was declared at the 0.05 probability level. Least squares means (LSMeans) were used to estimate treatment effect. Populations analyzed included the Full Analysis (intent-to-treat [ITT]) Set (FAS), Per-Protocol Set (PPS), Safety-Analyzable Set, and All-Screened Analysis Set. Demographic and baseline data for all subjects in the Safety-Analyzable Set were summarized and listed. The effects of treatment at the Overall and all other analysis Time Points were assessed using ANCOVA models. The main effects model contained terms for treatment and Investigator site, with baseline TSSC value as a covariate. The LSMeans and standard errors were based on the main effects model. Methods of analysis of secondary efficacy data included analysis of covariance (ANCOVA) models and Cochran-Mantel-Haenszel (CMH) row mean scores tests. Analysis of drug safety included the incidence of treatment-emergent AEs (TEAE), concomitant medications, vital signs, and physical examination findings for the Safety-Analyzable Set.

03

Conditions studied

  • Allergic Rhinitis
  • Hay Fever
  • SAR
  • Rhinitis, Allergic, Seasonal

Browse trials for

Keywords

  • SAR
  • seasonal allergic rhinitis
  • hay fever
  • seasonal allergic rhinoconjunctivitis
04

In context

Rhinitis, Allergic, Seasonal Reclassified

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

This study's enrollment of 683 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.

Browse Rhinitis, Allergic, Seasonal studies →

Lead sponsor

Johnson & Johnson Consumer and Personal Products Worldwide is the lead sponsor of 60 studies on the registry; none are open to participants now.

First submitted before Johnson & Johnson Consumer and Personal Products Worldwide left Johnson & Johnson.

Compared within Rhinitis, Allergic, Seasonal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Rhinitis, Allergic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 6 to 11 years of age.
  • Females who reached menarche either before or during the study, agreed to use acceptable methods of if they became sexually active. Acceptable birth control was defined as oral contraceptives or Norplant®.
  • Outpatient.
  • History and diagnosis of seasonal allergic rhinitis (SAR) to a prevalent allergen (grass or tree).
  • SAR to a prevalent allergen (grass or tree) of such severity that it required pharmacologic therapy each year for the last 2 consecutive years (including the present year).
  • Documented SAR to a prevalent allergen (grass or tree) as confirmed by a recognized skin test (prick, intradermal [ID], or Multitest®) within the previous 15 months (Prick/Puncture wheal® ≥3 mm over the negative control; ID [up to concentration of 1:1000 w/v or 1000 protein nitrogen units (PNU)] wheal® ≥5 mm over the negative control). Documentation of SAR must have occurred at Visit 1 or within 15 months prior to Visit 1. If not performed at Visit 1, SAR testing must have been performed in the Principal Investigator's office or full documentation must have been available prior to randomization.
  • Diary-recorded rhinoconjunctivitis symptom scores (24 hour reflective) that included at least two symptoms (sneezing, runny nose, itchy eyes, or watery eyes) at moderate severity (i.e., symptom score ≥2) on at least 4 days between Visits 1 and 2.
  • Diary-recorded TSSC score ≥5 (based on the four symptoms noted in the criteria above) on any 4 days between Visits 1 and 2.
  • Someone (subject and parent/legal guardian) from whom the Principal Investigator or study personnel would have expected conscientious cooperation over the duration of the study.
  • A written informed assent must have been provided by the subject and a written must have been provided by the parent/legal guardian at Visit 1.

Exclusion criteria

Exclusion Criteria:

  • Had nasal anatomical deformities with > 50% obstruction (i.e., septal defects, polyps).
  • Experienced an episode of acute sinusitis or an upper respiratory tract infection (URTI) including otitis media and the common cold) within 21 days of Visit 1.
  • Had a history of chronic sinusitis.
  • Initiated or advanced an immunotherapy regimen during the course of the study. Subjects receiving a maintenance dose of immunotherapy were eligible.
  • Had a history of attention deficit/hyperactivity disorder (ADHD) that was considered unstable by the Investigator, or if pharmacotherapy (i.e., Ritalin®, Adderall®) was required, subject must have been on pharmacotherapy for at least 1 month prior to Visit 1. The pharmacotherapeutic regimen was to remain stable during the conduct of the study.
  • Had a history of learning disabilities or intellectual impairment that, in the opinion of the Investigator, would prevent the subject from participating in the study.
  • Had impaired hepatic function (cirrhosis, hepatitis), glaucoma, or any symptomatic infection, any clinically significant hematologic, renal, endocrine, or gastrointestinal disease, and/or current neuropsychiatric condition with or without drug therapy, that was judged by the Investigator to be clinically significant and/or affect the subject's ability to participate in the clinical trial.
  • Had a history of (except basal cell carcinoma), epilepsy or seizures (excluding febrile seizures), excessive alcohol intake or drug addiction, hypertension, or other clinically significant cardiovascular disease.
  • Had a physical examination abnormality considered by the Investigator to be clinically significant and limiting to the study's conduct, unless the abnormality was related to underlying allergic rhinitis.
  • Had a history of an allergy or to cetirizine, loratadine, hydroxyzine, or any of their ingredients.
  • Had asthma, which required any of the following within the past 30 days: 1) admission to the hospital, 2) emergency room visit, or 3) a change in dosing regimen. Subjects were allowed to continue theophylline, long acting β2 agonists, inhaled cromoglycate no more than 6.4 mg/day, or nedocrimil no more than 14 mg/day. Subjects were allowed to continue inhaled in doses not exceeding those listed in Appendix B of the study protocol, as long as the dose did not change during the study. Subjects were allowed the use of short acting β2 agonists on an as needed (PRN) basis.
  • Had used intranasal or intra ophthalmic corticosteroids; oral leukotriene modifiers or leukotriene receptor antagonists within 14 days; or systemic (intramuscular and/or intravenous and/or oral) corticosteroids within 35 days prior to Visit 2. Topical corticosteroids for skin were allowed if covering ≤10% of body surface without occlusion.
  • Used intranasal cromolyn (Nasalcrom®), optical cromolyn (Crolom®), ipratropium bromide (Atrovent® Nasal Spray), azelastine hydrochloride (Astelin® Nasal Spray), monamine oxidase (MAO) inhibitors, or beta blockers for the treatment of migraine headaches within 14 days prior to Visit 2.
  • Used antiallergic ophthalmic treatments such as Acular®, Patanol®, or Alomide® within 7 days prior to Visit 2.
  • Used H1-receptor antagonists (oral and topical), H2-receptor antagonists, or decongestants after Visit 1.
  • Used tricyclic antidepressants, tranquilizers, or antiemetics of the phenothiazine class within 14 days prior to Visit 2.
  • Used oral macrolide antibiotics or oral antifungals within 7 days prior to Visit 2.
  • Used saline nasal spray or ocular drops (unless for contact lens use) within 72 hours prior to Visit 2.
  • Participated in any other studies involving or marketed products within 30 days prior to entry into the study or participated in studies which involved norastemizole, or monoclonal anti-immunoglobulin E (IgE) antibody within 90 days prior to entry into the study.
  • Donated blood or blood products for transfusion within 30 days prior to initiation of treatment with study drug and at any time during the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
683 participants (actual)

Study arms

  • Experimental
    Cetirizine 10 mg

    Cetirizine HCl 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive cetirizine HCl syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.

    Drug: Cetirizine

  • Active comparator
    loratadine 10 mg

    Loratadine 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive loratadine syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.

    Drug: Loratadine

  • Placebo comparator
    placebo

    Placebo syrup once daily for 2 weeks. Both placebo syrups were received by subjects who were randomized to receive placebo. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.

    Other: Placebo

Interventions

  • Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks

    Also known as: ZYRTEC

  • Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks

    Also known as: CLARITIN

  • OtherPlacebo

    Placebo syrup once daily before 10:00 AM for 2 weeks

07

What researchers measure

Primary outcomes

  1. Change from baseline to the Overall endpoint in the subject 24-hour reflective total symptom severity complex (TSSC) score

    Time frame: 2 weeks

Secondary outcomes

  1. Change from baseline to the Overall endpoint in the subject 24-hour reflective TSSC, with and without stuffy nose score

    Subject rated reflective TSSC on 5-point scale

    Time frame: 2 weeks

  2. Change from baseline to the Overall endpoint in the individual rhinoconjunctivitis symptoms (reflective and instantaneous)

    Subject rated individual symptom severity on 5-point scale (reflective and instantaneous)

    Time frame: 2 weeks

  3. Investigator evaluation of rhinoconjunctivitis symptoms

    Change from baseline to all secondary time points (Week 1 \[average of TSSC scores during Week 1 of double-blind treatment\], Week 2 \[average of TSSC scores during Week 2 of double-blind treatment\], and Endpoint \[last available post-baseline TSSC score\]) in subject 24-hour reflective TSSC.

    Time frame: 2 weeks

  4. Parent/legal guardian evaluation of subject's rhinoconjunctivitis symptoms

    Change from baseline to all secondary time points (Week 1 \[average of TSSC scores during Week 1 of double-blind treatment\], Week 2 \[average of TSSC scores during Week 2 of double-blind treatment\], and Endpoint \[last available post-baseline TSSC score\]) in subject 24-hour reflective TSSC.

    Time frame: 2 weeks

  5. Investigator Global Evaluations of Efficacy at Visit 4/early termination

    Investigator assess the therapeutic regimen's effect on 7-point scale

    Time frame: 2 weeks

  6. Subject/Parent/Legal Guardian Global Evaluations at Visit 4/early termination

    Subject/Parent/Legal Guardian provided global evaluation of treatment on a 5-point scale

    Time frame: 2 weeks

  7. Parent/Legal Guardian Overall Personal Satisfaction Assessment at Visit 4/early termination

    Parent/Legal Guardian provided appraisal of overall personal satisfaction with treatment on a 5-point scale

    Time frame: 2 weeks

  8. Parental Burden Questionnaire

    At Visits 2, 3, and 4/early termination, the parent/legal guardian assessed the social and emotional impact of caring for a child with SAR on a 5-point scale

    Time frame: 2 weeks

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2001, a primary completion of Jul 2001 and a completion of Jul 2001. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2016
First posted
Oct 13, 2016
Start
Mar 2001
Primary completionActual
Jul 2001
CompletionActual
Jul 2001
Last update
Apr 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02932774
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Oct 13, 2016
Start date
Mar 2001
Primary completion
Jul 2001
Completion
Jul 2001
Last update
Apr 20, 2017

Study contacts

Dial Hewlett, MD
study director · Medical Director; Pfizer, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetirizine

Start the discussion